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Abstract
Background: The author intended to clarify the therapeutic effect and prognostic factors of metastasectomy and timing of 
pulmonary metastases in osteosarcoma patents.
Methods: Data was obtained retrospectively on all consecutive osteosarcoma patients from 1985 to 2005 in author’s institute. 
Fifty-two patients with pulmonary nodules were identiﬁ  ed, including 24 patients undergoing pulmonary metastasectomy 
treatment. These patients were categorized into four groups: group 1, patients with lung metastases at the initial presentation; 
group 2, lung metastases identiﬁ  ed during the period of pre-operative chemotherapy; group 3, lung metastases identiﬁ  ed 
during period of the post-operative che motherapy; group 4, lung metastases identiﬁ  ed after therapy for the primary 
osteosarcoma completed.
Results: In our study, the 2-, 3-, and 5-year overall survival rates for 52 patients were 49%, 39% and 20%. The 2-year 
overall survival rates were 18% for group 1, 32% for group 3, and 70% for group 4 (p  0.001). The 5-year overall survival 
rate was 34% for group 4. Patients who underwent metastesectomy showed a better survival outcome as compared with the 
patients not undergoing metastasectomy (p = 0.003). The 2-year and 5-year overall survival rates of only one lung metastatic 
nodule were 62% and 50%, and for initially multiple lung metastatic nodules, 45% and 5%, respectively. In addition, the 
patients presented with lung metastases had a worse prognosis as compared with those without initial lung metastases 
(p = 0.0001).
Conclusions: The patients having single metastatic nodule showed a better prognosis than those with multiple lung nodules. 
Furthermore, those patients who underwent metastasectomy survived longer than those not undergoing metastasectomy. 
Patients who had late metastases after complete chemotherapy had a better prognosis; whereas those who had metastases 
identiﬁ  ed at the initial presentation predicted a poor prognosis.
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Introduction
Osteosarcoma is the most common malignant bone sarcoma in the children and adolescents. The 
long-term survival of patients with osteosarcoma has dramatically improved over the last two decades 
because of the combination of chemotherapy, local treatment and aggressive metastasectomies.
1–3 
The osteosarcoma patients without lung metastases had a 5-year survival rate around 65%–75%.
4–8 
However, pulmonary metastases occurs in approximately half of the osteosarcoma patients and 30% 
to 50% of the osteosarcoma patients still die of pulmonary metastasis.
2,3,9–11 The 5-year event-free 
survival rate of the patients with lung metastases was dramatically decreased, although it was 
improved from 0%–17% to 30%–50% over the last 2 decades.
9,12–24 Previous reports showed that 
approximately 15% to 20% of patients with osteosarcoma present with lung metastasis at initial 
diagnosis
14,25–27 and more than 75% of synchronous metastatic lesions are found in the lungs.
14,16,17,28 
Therefore, treatment of the osteosarcoma patients with pulmonary metastases remains a big challenge 
at present.
The pulmonary metastectomy, i.e. resection of the pulmonary metastatic nodules may improve 
prognosis of these patients.
9,17,22,24,29,30 The purpose of our study was to investigate the effect of timing 
of pulmonary metastases and the effect of metastasectomy in the survival of the osteosarcoma patients. 100
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We report a retrospective study of 52 osteosarcoma 
patients with pulmonary metastases at our institute 
in the past 20 years.
Materials and Methods
From January 1985 to July 2005, 52 patients hav-
ing osteosarcoma and lung metastases were treated 
in the authors’ institution. The patient’s average 
age was 17.5 years (range, 8 to 56 years) with 
35 males and 17 females. Twenty-seven patients 
had primary tumor located in the femur, 16 in the 
tibia, 6 in the humerus, and 2 in the femoral neck 
and 1 in the scapula. The mean follow-up duration 
was 28.6 months (range 4 to 129 months). Of all 
the patients, 24 patients underwent metastasectomy 
of lung metastatic nodules. Among them, four 
patients had lung metastases proved by chest plain 
radiography or computed topography at the initial 
clinical presentation. We also identiﬁ  ed the number 
of pulmonary nodules and classiﬁ  ed them as single 
(7 patiens) or multiple lesions(17 patients). The 
other 28 patients did not receive pulmonary metas-
tasectomy, and four of them were diagnosed with 
lung metastases at the initial clinical presentation. 
Twelve patients had single and 16 patients had 
multiple lung nodules.
In order to investigate the effect of timing of 
pulmonary metastases on the survival, we divided 
our 52 patients into four groups according to the 
time of lung metastases identification: group 
1, 11 patients with lung metastases at the initial 
presentation; group 2, 1 patient with lung metas-
tasis noted during the pre-operative chemotherapy 
period; group 3, 12 patients with lung metastases 
identiﬁ  ed during the post-operative chemotherapy 
period; group 4, 28 patients with their lung metas-
tases identiﬁ  ed after complete chemotherapy for 
the primary osteosarcoma (Fig. 1A). In addition to 
the timing of lung metastases and metastasectomy, 
we retrospectively investigated several prognostic 
factors including primary tumor site, and the num-
ber of pulmonary metastatic lesions at initial pre-
sentation. Chest surgeons were consulted for 
further evaluation and management. The criteria 
for metastasectomy include (1) primary tumor 
under control, (2) no other metastatic lesions 
except lung, (3) adequate residual lung volume. 
After discussion with the patient and the family, 
we suggested metastasectomy if the patients are 
suitable to undergo surgery. Unfortunately, most 
patients didn’t undergo metastasectomy due to poor 
response to chemotherapy (rapid progression of 
disease) or complications of chemotherapy 
(neutropenic fever or sepsis).
The limb salvage operation was the preferred 
procedure to treat osteosarcoma patients. Most 
patients received preoperative chemotherapy, 
operation, and postoperative chemotherapy as 
scheduled. The major regimen of chemotherapy 
included cycles of cisplatin plus epirubicin or 
adramycin, etoposide plus cyclophospamid or 
ifosphamide. High-dose methotrexate (8 g/m
2 for 
patients older than 12 years, 12 g/m
2 for youger 
patients) was given with oral leucovorin rescue. 
The dose or regimen of chemotherapy would 
adjust according to the response of chemotherapy 
and the patients’ compliance. Lung metastatic 
lesion would be removed after complete therapy 
of primary osteosarcoma lesion. All osteosarcoma 
Diagnosis       Surgery Completion of therapy
pre-operative 
chemotherapy 
postoperative 
chemotherapy 
with
metastasectomy 
4 0 7  13 
without 
metastastectomy 
7 1 5  15 
Group 1(n = 11) Group 2(n = 1) Group 3(n = 12) Group 4(n = 28)
Figure 1. A demographic data of the patients in our study. These patients were divided into four groups according to the time of presenting 
lung metastases. Group 1, patients with initial lung metastases at presentation, group 2, lung metastases identiﬁ  ed during the pre-operative 
chemotherapy period, group 3, lung metastases identiﬁ  ed during the post-operative chemotherapy period, group 4, lung metastases identiﬁ  ed 
after complete chemotherapy for the primary osteosarcoma.101
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patients receiving metastasectomy had further 
chemotherapy.
Survival curve was analyzed by the method of 
Kaplan and Meier, and the signiﬁ  cance of differ-
ence among groups were analyzed by log-rank test. 
A p-value of less than 0.05 was considered sig-
niﬁ  cant.
Results
The 2-, 3-, and 5-year overall survival rates for 
these 52 patients were 49%, 39% and 20% 
(Fig. 2A). Figure 2B showed the patients with lung 
metastases at initial presentation (Enneking stage 
IIIB) had a worse prognosis than those without 
initial lung metastases (Enneking stage IIB) 
(p = 0.017). The patients without initial lung 
metastasis showed a better survival rate and it could 
be recognized as a prognostic factor. The overall 
2-year survival rates were 18% for group 1, 0.1% 
for group 2, 32% for group 3, and 70% for group 4. 
The 5-year survival rate was 34% for group 
4 patients (Fig. 2C). Only group 4 patients (lung 
metastases after complete therapy) can survive for 
more than 5 years, and they had a signiﬁ  cantly 
better prognosis than the patients of other groups 
(p  0.001). Figure 2D showed the relationship of 
the number of lung metastatic nodules on the sur-
vival rate of the patients with osteosarcoma. The 
patients with single metastatic nodule showed 
a statistically signiﬁ  cant better prognosis than those 
patients with multiple lung nodules at presentation 
(p = 0.017). The 2-year and 5-year overall survival 
rates of single lung metastatic nodule were 62% 
and 50%, respectively. The 2-year and 5-year 
overall survival rate of initial multiple lung meta-
static nodules were 45% and 5%. The number of 
lung metastatic nodules at initial presentation is a 
prognostic factor for osteosarcoma patients.
The most common sites of osteosarcoma were 
distal femur, proximal tibia and proximal humerus. 
Patients with primary osteosarcoma at distal femur 
and proximal tibia showed a better prognosis than 
those with tumor located in other sites (Fig. 2E). 
It was statistically signiﬁ  cant if the patients can 
survive more than 5 years (p = 0.026).
Patients who underwent metastasectomy 
showed a signiﬁ  cantly better survival outcome 
(Fig. 3A) (p  0.05). We analyzed the survival 
outcomes the patients either undergoing metasta-
sectomy or not separately. Among all four groups, 
the group 4 patients had the best survival prognosis, 
no matter undergoing metastasectomy (p = 0.0081) 
or not undergoing metastasectomy (p = 0.0006) 
(Fig. 3B). Furthermore, if we analyzed effects of 
metastasectomy in the patients at different time of 
presentation of lung metastases in these four 
groups, we still can find a trend that patients 
who underwent metastasectomy had a better 
prognosis (Fig. 3C).
Discussion
The recent advance in the chemotherapy, aggressive 
surgical treatment and image studies improved the 
survival outcomes and functions in the patients with 
osteosarcoma. Bacci et al reported their 5-year and 
10-year survival of these patients as 66% and 57%, 
respectively.
31 However, half of these patients still 
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Figure 2A. Overall survival rate for the osteosarcoma patients with 
pulmonary metastases.
Figure 2B. Patients with Enneking stage IIIB (lung metastasis) at 
initial presentation had a worse survival prognosis than those with 
IIB osteosarcoma.102
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develop lung metastases and the survival outcome 
was much worse as compared with those without 
lung metastases. From January 1985 to July 2005, 
there were two hundred and ten osteosarcoma diag-
nosed in our institute. Among them, only four pelvic 
(2%) osteosarcoma were found. In our study, these 
four patients didn’t develop pulmonary metastases. 
Similar results had been presented by Sabb et al 
Cancer Apr 1, 2005, Volume 103.
7,32 Among 442 
osteosarcoma patients, 19 patients (4%) had primary 
tumor in the pelvic bones. Only 4 patients developed 
pulmonary metastases in their groups.
The 5-year overall survival rate in the osteosar-
coma patients with lung metastases was 20% in 
our series. However, these survival outcomes may 
still give hope and encouragement to try a more 
chemotherapy and aggressive treatment for those 
patients with pulmonary nodules. However, 
the patients with pulmonary metastases after com-
plete therapy (group 4) can have a 2-year survival 
rate 82% and 5-year survival rate, 55%. Even the 
group 4 patients without metastasectomy still had 
a 2-year and 5-year survival rate up to 52% and 
18%. It implies that a more aggressive treatment 
policy should be considerated. The survival of 
nonmetastatic osteosarcoma patients showed a 
dramatically better prognosis.
8 However, we can 
ﬁ  nd better prognostic factors in pulmonary metas-
tasic patients, such as sites, the number of pulmo-
nary nodule, staging, metastasectomy, and the 
timing of pulmonary metastases presentation. 
Hawkins et al also identified that the factors 
improving survival rates were unilateral pulmonary 
recurrence, solitary pulmonary nodules at recur-
rence, more than 24 months between the initial 
diagnosis and ﬁ  rst disease recurrence, and achieve-
ment of a second complete response.
33
Many reports advocated that a complete metas-
tasectomy is a better predictor factor of survival in 
osteosarcoma patients with pulmonary metasta-
ses.
9,10,14,19 Even repeated thoracotomy for recur-
rent pulmonary metastases has been proved 
beneficial to patients.
17,34 In our series, most 
patients underwent multiple surgeries for pulmo-
nary metastatic nodules. We also obey the princi-
ples to treat the metastatic lung nodules. We 
suggested that metastasectomy may present as a 
good prognostic factor in osteosarcoma patients. 
If we perform as more aggressive surgery for lung 
Figure 2C. Overall survival probability for osteosarcoma patients 
according to the timing of pulmonary metastses. Group 4 patients 
had the best prognosis.
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Figure 2D. Patients with single metastatic lung nodule had a better 
survival prognosis as compared with those with multiple lung 
nodules.
 
 0       12       24       36      48      60       72       84     96      108    120    132
Survival Time (Months)
S
u
r
v
i
v
a
l
 
P
r
o
b
a
b
i
l
i
t
y
0.00
0.20
0.40
0.60
0.80
1.00
1: Tibia; 2: Femur; 3: Humerus;
4: Femoral neck; 5: Scapula
Figure 2E. Cumulative survival curves for the primary tumor sites 
showed better results for those with the tumor located at the distal 
femur and proximal tibia. (Group 1: proximal tibia, group 2: distal femur, 
group 3: upper extremity, group 4: femoral neck; group 5: scapula).103
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metastatic nodules as possible, we can increase the 
survival rate even the patients with lung metastases. 
Briccoli et al
34 also proposed that we should 
perform re-operation for recurrent pulmonary 
metastases due to similar disease-free interval after 
five years. In their study, the 3- and 5-year 
event-free survival rate was 45% and 38%, respec-
tively; whereas from the second metastasecotmy, 
it was 33% and 32%, respectively. A study done 
by Snyder et al
35 also supported that aggressive 
thoracotomy from bone and soft-tissue sarcoma 
should be considered when there is control of local 
disease, no evidence of extrapulmonary metastasis, 
and adequate postresection pulmonary reserve. 
They even performed thoracotomy on patients with 
bilateral, extensive, or recurrent pulmonary 
metastasis.
The effect of timing of pulmonary identiﬁ  cation 
remains equivocal. Some studies showed that the 
patients having initial presentation of lung 
metastases had worse prognosis,
13,14,36–39 and other 
studies do not show the same relationship. For 
example, Yonemoto et al
22 claimed that the 5-year 
survival rate of osteosarcoma with pulmonary 
metastasis at initial presentation was 64.8%, which 
is not different from patients without pulmonary 
metastasis at initial presentation (62.1%). He also 
held that the studies with poor prognosis is due to 
inconsistent treatment. More aggressive 
chemotherapy and surgery should improve the 
survival.
In our study, the patients with lung metastases 
after complete therapy (Group 4) showed the best 
prognosis. Tsuchiya et al
40 classiﬁ  ed his patients 
with the same criteria we used in this study. He 
reported overall a 5-year survival rates of 18% for 
group 1, 0% for group 2, 6% for group 3, and 31% 
for group 4. Their group 4 patients also demonstrated 
a better prognosis than other groups.
We also find that the patients with lung 
metastases at initial presentation did not show 
the worst prognosis, as compared with the 
patients in group 2 and group 3. It may be due to 
the activation of angiogenic activity after 
resection of osteosarcoma tumor.
41 It may remind 
us that a new treatment or more aggressive 
chemotherapy protocols, e.g. antiangiogenesis 
therapy, should be applied to those patients with 
pulmonary metastases when chemotherapy 
is ongoing. However, we still need to keep in 
mind the potential sources of bias due to the 
heterogeneity of the subgroups and the small size 
of the sample.
Figure 3A. Kaplan-Meier survival curves showed better prognosis 
in the patients with metastasectomy., when comparing with patients 
who did not receive metastasectomy.
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Figure 3B. Survival for each group according to the timing of pulmonary 
metastases without (a) and with (b) metastasectomy. Group 4 patients 
had a better prognosis than the patients in the other groups.104
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In conclusion, this study ensures that the good 
prognostic factors among the osteosarcoma patients 
with lung metastases were: 1. primary tumor sites 
at distal femur and proximal tibia, 2. staging IIB, 
3. metastasectomy, 4. pulmonary metastases iden-
tiﬁ  ed after complete treatment. According to our 
data, the close follow-up of the patients with osteo-
sarcoma during the chemotherapy period is manda-
tory due to the possibility of the development of 
new lesions in lungs. The effect of metastasectomy 
has also been shown in this study. we recom-
mended that osteosarcoma patients with pulmonary 
metastatic nodules, even for those with worse 
prognostic factors, should receive further chemo-
therapy as well as more aggressive surgery.
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